))
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
Manage episode 402377703 series 2838329
Contenu fourni par VJHemOnc. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par VJHemOnc ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells and antibody-based therapies. Despite these advances, several challenges remain in the field. In today's episode, you will hear the latest updates with the use of CAR-T therapy in ALL, as discussed by renowned experts during the EBMT-EHA 6th European CAR T-cell meeting.
In this podcast, André Baruchel, MD, PhD, Hospital Robert Debré AP-HP, Paris, France, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and Alex Rampotas, MD, University College London, London, UK, cover several topics, including challenges with administering CAR-T therapy in B- and T-ALL, the possibility of exploring dual-targeting of CD19 and CD22 to overcome resistance, considerations for managing patients with B-ALL prior to CAR-T therapy, and more.
200 episodes
Partager
